Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Rui Wang
Institution:
First Affiliated Hospital of Bengbu Medical College
Observed institution:
First Affiliated Hospital of Bengbu Medical College
ORCID:
0009-0004-5467-9060
Observed ORCID:
0009-0004-5467-9060
OpenAlex ID:
A5092471387
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
2025
·
Jian Zhou
, Li Bai
, et al.
·
The Lancet Oncology
·
80
HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer
2023
·
Tao Jiang
, Qiqi Jin
, et al.
·
Clinical Cancer Research
·
18
Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor–Related Bone Metastases: A Randomized, Double-Blind, Phase 3 Equivalence Trial
2024
·
Shaohua Zhang
, Yongmei Yin
, et al.
·
JAMA Oncology
·
8
PDF
Clinical effects of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy on complications and recurrence in patients with advanced gastric cancer
2024
·
Rui Wang
, Meng Li
, et al.
·
Pakistan Journal of Medical Sciences
·
1
Supplementary Data 1 from HLA-I evolutionary divergence confers response to PD-1 blockade plus chemotherapy in untreated advanced non-small-cell lung cancer
2024
·
Tao Jiang
, Qiqi Jin
, et al.
Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer
2023
·
Tao Jiang
, Qiqi Jin
, et al.
PDF
Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer
2023
·
Tao Jiang
, Qiqi Jin
, et al.
Data from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer
2023
·
Tao Jiang
, Qiqi Jin
, et al.
Data from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer
2023
·
Tao Jiang
, Qiqi Jin
, et al.
Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer
2023
·
Tao Jiang
, Qiqi Jin
, et al.
PDF
Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer
2023
·
Tao Jiang
, Qiqi Jin
, et al.
Show more works
View as search
Works count:
11
Citation count:
107
H-index:
3
I10-index:
2
Year
Topic
Type